Fluence

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

2024-08-27T14:01:21+02:00July 25, 2024|Investor Information, Press Releases, Psychedelic News|

Psyence Biomed today announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial evaluating nature‑derived psilocybin as a potential treatment for Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context.

Read More

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

2024-08-27T10:00:45+02:00April 9, 2024|Investor Information, Press Releases|

has entered into a partnership with Fluence, a global leader in professional education and training for psychedelic therapy research, and iNGENū CRO Pty Ltd (“iNGENū”), an Australian clinical research organization (CRO), to support an upcoming Phase llb clinical trial. The trial will explore the efficacy and safety of psilocybin-assisted psychotherapy (PAP) for the treatment of Adjustment Disorder due to a recent cancer diagnosis in the Palliative Care context.

Read More

Contact Info

General inquiries — info@psyencebiomed.com

Investor inquiries — ir@psyencebiomed.com

Tel: +1-416-477-1708

Address: 121 Richmond Street West, Penthouse Suite, 1300, Toronto ON M5H2K1, Canada

Sign Up To Our Newsletter

Sign Up To Receive Our Communications

By submitting this form, you are consenting to receive marketing emails from: Psyence Group Inc, 121 Richmond Street West, Penthouse Suite, 1300, Toronto ON M5H2K1 Canada You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
Go to Top